Blog
RSS FeedPosted by Michael Wonder on 26 Oct 2023
ViiV Healthcare receives approval from China’s National Medical Products Administration for Vocabria (cabotegravir) used in combination with Rekambys (rilpivirine), the first and only complete long-acting HIV-1 injectable treatment
26 October 2023 - The marketing authorisation for rilpivirine long-acting injection was received on the 18 October 2023. ...
Posted by Michael Wonder on 25 May 2023
Gilead and Teva defend antitrust claims that prices for HIV medicines were unfairly kept high
25 May 2023 - Amid concern that HIV prevention pills are not being widely taken by those at highest risk ...
Posted by Michael Wonder on 24 Mar 2022
U.S. FDA approves streamlined process for initiating HIV therapy with Cabenuva (cabotegravir and rilpivirine), the first and only complete long-acting injectable HIV treatment
24 March 2022 - Adults living with HIV now have an option to start injectable regimen without the need for ...
Posted by Michael Wonder on 14 Feb 2022
Members of Congress ask CDC to cut cost of new HIV prevention drug
11 February 2022 - “Only by making Apretude free can we fulfill its promise to liberate millions of people, particularly LGBTQ+ ...
Posted by Michael Wonder on 07 Jul 2021
'This will shut us down': HIV prevention clinics brace for Gilead reimbursement cuts
7 July 2021 - An expected funding loss of at least $100 million annually will soon drain front-line clinics, threatening the ...
Posted by Michael Wonder on 24 Feb 2021
ViiV Healthcare submits supplemental new drug application to US FDA for expanded use of Cabenuva (cabotegravir, rilpivirine) as an HIV treatment for use every 2 months
24 February 2021 - ViiV Healthcare announced today the submission of a supplemental new drug application to the US FDA for ...
Posted by Michael Wonder on 21 Jan 2021
FDA approves first extended release, injectable drug regimen for adults living with HIV
21 January 2021 - The U.S. FDA today approved Cabenuva (cabotegravir and rilpivirine, injectable formulation) as a complete regimen for the ...
Posted by Michael Wonder on 01 Sep 2020
Roche receives FDA approval for first HIV-1/HIV-2 Qualitative Test on the cobas 6800/8800 Systems in the fight against HIV/AIDS
1 September 2020 - Detects, confirms and differentiates HIV-1 and HIV-2 infections providing clinicians with critical diagnostic data for personalised management ...
Posted by Michael Wonder on 11 Aug 2020
China National Medical Products Administration approves Truvada for HIV pre-exposure prophylaxis
11 August 2020 - Truvada is the first HIV PrEP medicine approved in China. ...
Posted by Michael Wonder on 06 Jul 2020
Access to HIV medicines severely impacted by COVID-19 as AIDS response stalls
6 July 2020 - Countries seek innovative ways to mitigate the impact of disruptions and keep services going. ...
Posted by Michael Wonder on 13 Apr 2020
Gilead Canada submits supplemental new drug submission to Health Canada for Descovy for HIV pre-exposure prophylaxis
9 April 2020 - Submission supported by data from the DISCOVER trial, which evaluated the safety and efficacy of Descovy compared ...
Posted by Michael Wonder on 16 Mar 2020
HIV drug PrEP to be available across England
15 March 2020 - PrEP will be routinely available across England as part of the government’s aim to end HIV transmission ...
Posted by Michael Wonder on 29 Aug 2019
PrEP school: a field manual for the battle over HIV prevention drug pricing
29 August 2019 - Pre-exposure prophylaxis (PrEP)—an HIV prevention intervention consisting of a daily drug cocktail, quarterly HIV/sexually transmitted disease screening, ...
Posted by Michael Wonder on 22 Aug 2019
Gilead files challenge to government patents for HIV prevention pill
21 August 2019 - Gilead Sciences took the unusual step of mounting a challenge to U.S. government patents on Wednesday, ...
Posted by Michael Wonder on 12 Aug 2019
China National Medical Products Administration approves Biktarvy (bictegravir, emtricitabine and tenofovir alafenamide) for treatment of HIV-1 infection
9 August 2019 - Biktarvy demonstrated high efficacy and a high barrier to resistance in clinical trials through 48 weeks. ...